×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RGEN – repligen corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RGEN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/10
05:48 am
rgen
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
Medium
Report
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings? [Yahoo! Finance]
4/8
07:30 am
rgen
Repligen Appoints Jacob Johnson As Vice President Investor Relations
Medium
Report
Repligen Appoints Jacob Johnson As Vice President Investor Relations
4/4
11:30 pm
rgen
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/18
11:24 am
rgen
Repligen down 7% as Evercore initiates in-line [Seeking Alpha]
Low
Report
Repligen down 7% as Evercore initiates in-line [Seeking Alpha]
3/18
08:06 am
rgen
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $155.00 price target on the stock.
Medium
Report
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $155.00 price target on the stock.
3/11
06:45 am
rgen
A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]
Medium
Report
A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack [Yahoo! Finance]
3/4
08:05 am
rgen
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices [Yahoo! Finance]
Low
Report
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices [Yahoo! Finance]
3/4
07:30 am
rgen
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Low
Report
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/4
04:26 pm
rgen
Form ARS REPLIGEN CORP For: Dec 31
Medium
Report
Form ARS REPLIGEN CORP For: Dec 31
4/4
04:16 pm
rgen
Form DEF 14A REPLIGEN CORP For: Apr 03
Medium
Report
Form DEF 14A REPLIGEN CORP For: Apr 03
4/2
10:34 am
rgen
Form 4 REPLIGEN CORP For: Apr 01 Filed by: Bylund James
Low
Report
Form 4 REPLIGEN CORP For: Apr 01 Filed by: Bylund James
3/20
01:52 pm
rgen
Form 4 REPLIGEN CORP For: Mar 13 Filed by: Bylund James
Low
Report
Form 4 REPLIGEN CORP For: Mar 13 Filed by: Bylund James
3/19
04:21 pm
rgen
Form 4 REPLIGEN CORP For: Mar 17 Filed by: Hunt Anthony
Medium
Report
Form 4 REPLIGEN CORP For: Mar 17 Filed by: Hunt Anthony
3/18
03:58 pm
rgen
Form 4 REPLIGEN CORP For: Mar 17 Filed by: Pax Margaret
Low
Report
Form 4 REPLIGEN CORP For: Mar 17 Filed by: Pax Margaret
3/17
04:27 pm
rgen
Form PRE 14A REPLIGEN CORP For: Mar 17
Medium
Report
Form PRE 14A REPLIGEN CORP For: Mar 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/3
Edwards Lifesciences Shows Improved Price Strength & IBD Rating Upgrade [Investor's Business Daily]
8.7%
7/15 Form 8-K REPLIGEN CORP For: Jul 15 7.9%
10/31 Repligen Exits Third Quarter Armed With a $500 Million War Chest [The Motley Fool] 6.6%
4/22 Repligen to Report First Quarter 2020 Financial Results 5.4%
3/10 Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 4.8%
6/4 Repligen to Present at Jefferies 2019 Healthcare Conference 4.8%
4/28 Form DEF 14A REPLIGEN CORP For: May 13 4.6%
11/14 Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 3.4%
5/9 Q1/2019 3/31/2019 EPS 0.280 ZacksConsensus 0.260 ActVsEst 0.020 - Beat 3.4%
5/15 Form 4 REPLIGEN CORP For: May 13 Filed by: Snodgres Jon 3.3%
7/15 Form 8-K REPLIGEN CORP For: Jul 15 7.9%
10/31 Repligen Exits Third Quarter Armed With a $500 Million War Chest [The Motley Fool] 6.6%
4/22 Repligen to Report First Quarter 2020 Financial Results 5.4%
3/10 Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 4.8%
6/4 Repligen to Present at Jefferies 2019 Healthcare Conference 4.8%
4/28 Form DEF 14A REPLIGEN CORP For: May 13 4.6%
11/14 Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 3.4%
5/9 Q1/2019 3/31/2019 EPS 0.280 ZacksConsensus 0.260 ActVsEst 0.020 - Beat 3.4%
5/15 Form 4 REPLIGEN CORP For: May 13 Filed by: Snodgres Jon 3.3%
TOP News Decliners
3/13
IBD Watchlists See Frothy Tide Of Incoming Stocks Amid Coronavirus Correction [Investor's Business Daily]
-11.7%
3/23 Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock. -10.2%
3/18 Form 4 REPLIGEN CORP For: Mar 16 Filed by: RYAN THOMAS F JR -9.8%
2/20 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results -8.1%
2/24 Form 4 REPLIGEN CORP For: Feb 21 Filed by: DAWES KAREN A -7.7%
8/1 Form 10-Q REPLIGEN CORP For: Jun 30 -6.7%
8/2 Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.7%
8/1 Q2/2019 6/30/2019 EPS 0.310 ZacksConsensus 0.250 ActVsEst 0.060 - Beat -4.3%
4/6 Form 4 REPLIGEN CORP For: Apr 03 Filed by: BARTHELEMY NICOLAS -3.5%
2/6 Repligen to Report Fourth Quarter and Full Year 2019 Financial Results -3.4%
3/23 Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock. -10.2%
3/18 Form 4 REPLIGEN CORP For: Mar 16 Filed by: RYAN THOMAS F JR -9.8%
2/20 Repligen Reports Fourth Quarter and Full Year 2019 Financial Results -8.1%
2/24 Form 4 REPLIGEN CORP For: Feb 21 Filed by: DAWES KAREN A -7.7%
8/1 Form 10-Q REPLIGEN CORP For: Jun 30 -6.7%
8/2 Repligen Corporation (RGEN) CEO Tony Hunt on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.7%
8/1 Q2/2019 6/30/2019 EPS 0.310 ZacksConsensus 0.250 ActVsEst 0.060 - Beat -4.3%
4/6 Form 4 REPLIGEN CORP For: Apr 03 Filed by: BARTHELEMY NICOLAS -3.5%
2/6 Repligen to Report Fourth Quarter and Full Year 2019 Financial Results -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: